GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Carna Biosciences Inc (TSE:4572) » Definitions » Price-to-Owner-Earnings

Carna Biosciences (TSE:4572) Price-to-Owner-Earnings : (As of Sep. 22, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Carna Biosciences Price-to-Owner-Earnings?

As of today (2024-09-22), Carna Biosciences's share price is 円395.00. Carna Biosciences does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Carna Biosciences's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Carna Biosciences was 750.20. The lowest was 45.06. And the median was 144.21.


TSE:4572's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.375
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-09-22), Carna Biosciences's share price is 円395.00. Carna Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was 円-78.84. Therefore, Carna Biosciences's PE Ratio for today is At Loss.

As of today (2024-09-22), Carna Biosciences's share price is 円395.00. Carna Biosciences's EPS without NRI for the trailing twelve months (TTM) ended in was 円-78.49. Therefore, Carna Biosciences's PE Ratio without NRI for today is At Loss.

During the past 13 years, Carna Biosciences's highest PE Ratio without NRI was 993.03. The lowest was 0.00. And the median was 54.58.


Carna Biosciences Price-to-Owner-Earnings Historical Data

The historical data trend for Carna Biosciences's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carna Biosciences Price-to-Owner-Earnings Chart

Carna Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Carna Biosciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Carna Biosciences's Price-to-Owner-Earnings

For the Biotechnology subindustry, Carna Biosciences's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Price-to-Owner-Earnings falls into.



Carna Biosciences Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Carna Biosciences's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=395.00/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Carna Biosciences  (TSE:4572) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Carna Biosciences Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Carna Biosciences's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Carna Biosciences Business Description

Traded in Other Exchanges
N/A
Address
BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences, Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines primarily for the treatment of cancer and inflammatory diseases using own innovative kinase drug discovery platform, QuickScout.

Carna Biosciences Headlines

No Headlines